SCM
ABBV icon

Shelton Capital Management’s AbbVie ABBV Stock Holding History

Shelton Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,900
Closed -$308K – 714
2022
Q1 		$308K Buy
+1,900
New +$276K 0.01% 533

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Shelton Capital Management's ABBV Position: Q1 2026 in Review

Shelton Capital Management increased its AbbVie (ABBV) stake by 3.8% in Q1 2026, buying an estimated $397K and bringing the position to 49,244 shares worth $10.7M. The position accounts for 0.23% of the portfolio, ranked #97.

Shelton Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.5M in Q2 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Shelton Capital Management held 49,244 shares of AbbVie worth $10.7M as of Q1 2026.
  • Shelton Capital Management bought 1,789 AbbVie shares in Q1 2026, an estimated $397K.
  • AbbVie made up 0.23% of Shelton Capital Management's portfolio in Q1 2026, its #97 holding.
  • Shelton Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Shelton Capital Management's AbbVie position peaked at $21.5M in Q2 2024.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Shelton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.